HC Wainwright Issues Optimistic Forecast for IPSC Earnings

Posted by Brenda Bartman on May 21st, 2026

Century Therapeutics, Inc. (NASDAQ:IPSC – Free Report) – Research analysts at HC Wainwright raised their Q2 2026 earnings per share estimates for Century Therapeutics in a research report issued to clients and investors on Tuesday, May 19th. HC Wainwright analyst M. Kapoor now expects that the company will earn ($0.11) per share for the quarter, up from their prior forecast of ($0.21). HC Wainwright currently has a “Buy” rating and a $5.00 target price on the stock. The consensus estimate for Century Therapeutics’ current full-year earnings is ($0.62) per share. HC Wainwright also issued estimates for Century Therapeutics’ Q3 2026 earnings at ($0.11) EPS, Q4 2026 earnings at ($0.12) EPS, FY2026 earnings at ($0.45) EPS, Q1 2027 earnings at ($0.12) EPS, Q2 2027 earnings at ($0.12) EPS, Q3 2027 earnings at ($0.13) EPS, Q4 2027 earnings at ($0.13) EPS and FY2027 earnings at ($0.49) EPS.

Century Therapeutics (NASDAQ:IPSC – Get Free Report) last issued its earnings results on Wednesday, May 13th. The company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.04.

A number of other equities analysts have also weighed in on IPSC. Wall Street Zen lowered Century Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Century Therapeutics in a research report on Monday, April 6th. TD Cowen started coverage on Century Therapeutics in a research report on Wednesday, February 25th. They set a “buy” rating on the stock. Zacks Research lowered Century Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, March 12th. Finally, Leerink Partners set a $2.00 target price on Century Therapeutics and gave the stock a “market perform” rating in a research report on Friday, March 13th. Three equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Century Therapeutics presently has an average rating of “Hold” and an average target price of $3.67.

View Our Latest Report on Century Therapeutics

Century Therapeutics Stock Up 6.1%

Shares of NASDAQ:IPSC opened at $2.25 on Thursday. Century Therapeutics has a twelve month low of $0.44 and a twelve month high of $3.04. The stock’s 50 day moving average is $2.31 and its 200-day moving average is $1.69. The firm has a market capitalization of $405.79 million, a price-to-earnings ratio of -1.97 and a beta of 1.55.

Insider Buying and Selling

In related news, insider Gregory Russotti sold 10,076 shares of the stock in a transaction on Thursday, March 12th. The stock was sold at an average price of $2.55, for a total value of $25,693.80. Following the completion of the sale, the insider directly owned 515,427 shares of the company’s stock, valued at approximately $1,314,338.85. This represents a 1.92% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Over the last ninety days, insiders sold 17,862 shares of company stock valued at $45,488. Corporate insiders own 4.37% of the company’s stock.

Institutional Investors Weigh In On Century Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Quadrant Private Wealth Management LLC raised its position in Century Therapeutics by 31.0% in the 1st quarter. Quadrant Private Wealth Management LLC now owns 20,022 shares of the company’s stock valued at $45,000 after buying an additional 4,736 shares during the last quarter. Geode Capital Management LLC raised its position in Century Therapeutics by 2.4% in the 4th quarter. Geode Capital Management LLC now owns 456,115 shares of the company’s stock valued at $454,000 after buying an additional 10,806 shares during the last quarter. Bank of New York Mellon Corp purchased a new stake in Century Therapeutics in the 1st quarter valued at $29,000. Bank of America Corp DE raised its position in Century Therapeutics by 109.1% in the 4th quarter. Bank of America Corp DE now owns 66,043 shares of the company’s stock valued at $67,000 after buying an additional 34,466 shares during the last quarter. Finally, Goldman Sachs Group Inc. raised its position in Century Therapeutics by 26.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 179,635 shares of the company’s stock valued at $86,000 after buying an additional 38,052 shares during the last quarter. 50.20% of the stock is owned by hedge funds and other institutional investors.

About Century Therapeutics

(Get Free Report)

Century Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of allogeneic cell therapies for cancer. Utilizing induced pluripotent stem cell (iPSC) technology, the company engineers “off-the-shelf” natural killer (NK) and T cell candidates designed to target hematologic malignancies and solid tumors. By harnessing iPSC-derived immune cells, Century aims to overcome challenges associated with patient-derived therapies, such as manufacturing variability and treatment delays.

The company’s proprietary platform integrates gene editing, synthetic biology and scalable cell expansion processes to generate a pipeline of product candidates.